- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03015389
Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
July 21, 2020 updated by: CDx Diagnostics
This is a multi-center, prospective, randomized study which will enroll patients undergoing endoscopic surveillance due to a history of histologically confirmed dysplasia.
A member of the research team will approach a potential subject to discuss participation in the study, including background of the proposed study, inclusion and exclusion criteria, benefits and risks of the procedures and follow-up.
If this is of interest to the subject, the informed consent form is discussed and presented.
The subject must sign the consent form prior to enrollment.
This form will have prior approval of the study site's Institutional Review Board (IRB).
Failure to obtain informed consent renders the subject ineligible for the study.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
170
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leuven, Belgium, 3000
- UZ Leuven - Campus Gasthuisberg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Barrett's associated esophageal dysplasia
Description
Inclusion Criteria:
- Patients age: ≥ 18 years
- Patients should have a history of Barrett's associated esophageal dysplasia (either low or high-grade) confirmed on histology
- Willingness to undergo both WATS3D and random forceps biopsies while undergoing conventional EGD with sedation
- Ability to provide written, informed consent (approved by IRB) and understand the responsibilities of trial participation
- Only patients who no visible mucosal abnormalities at the time that they undergo both random forceps biopsies and WATS3D testing of the esophagus will be included in this study
Exclusion Criteria:
- Coagulopathy with INR > 2.0, thrombocytopenia with platelet counts < 50,000
- The subject is pregnant or planning a pregnancy during the study period
- History of esophageal or gastric surgery other than Endoscopic Mucosal Resection (EMR)
- Patients who have undergone endoscopic ablative therapies
- Subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines
- Study patients with inadequate WATS3D specimens will not undergo a repeat brush biopsy test and will be excluded from the study
- BE length < 1 cm or > 10 cm
- Patients within six weeks of receiving targeted forceps biopsies and/or EMR
- Patients with visible mucosal abnormality at the time of the WATS3D and random biopsy testing
- Patients with visible lesions that are either submucosal or covered with a clinically intact epithelium
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Barrett's associated esophageal dysplasia
|
WATS3D brush biopsy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Detection rate of Barrett's associated high grade esophageal dysplasia and esophageal adenocarcinoma (HGD/EAC) using WATS3D and random 4 quadrant forceps biopsies taken at 2 cm intervals.
Time Frame: up to 2 years
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with Barrett's related dysplasia and adenocarcinoma diagnosed with random forceps biopsies and WATS3D biopsies used in alternating fashion.
Time Frame: up to 2 years
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Raf Bisschops, MD, University Hospitals Leuven, Dept. of Gastroenterology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 27, 2017
Primary Completion (ACTUAL)
February 18, 2019
Study Completion (ACTUAL)
February 18, 2019
Study Registration Dates
First Submitted
January 5, 2017
First Submitted That Met QC Criteria
January 6, 2017
First Posted (ESTIMATE)
January 10, 2017
Study Record Updates
Last Update Posted (ACTUAL)
July 23, 2020
Last Update Submitted That Met QC Criteria
July 21, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDx 810
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Barrett Esophagus
-
Erbe Elektromedizin GmbHNAMSA; Kansas City Veteran Affairs Medical Center; Erbe USA IncorporatedTerminatedBarrett's Esophagus | High-grade Dysplasia in Barrett Esophagus | Low Grade Dysplasia in Barrett EsophagusUnited States
-
University Medical Center GroningenCompletedEsophageal Cancer | Barrett Esophagus | Dysplasia in Barrett EsophagusNetherlands
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedBarrett Esophagus | Barrett AdenocarcinomaNetherlands
-
Mayo ClinicTerminatedBarretts Esophagus With High Grade Dysplasia | Barrett AdenocarcinomaUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina... and other collaboratorsNot yet recruitingEsophageal Cancer | Barrett Adenocarcinoma | Barretts Esophagus With Dysplasia
-
Portsmouth Hospitals NHS TrustUniversity of PortsmouthUnknownBarrett Esophagus | Barrett Adenocarcinoma | Barrett Metaplasia | Barrett Oesophagitis With DysplasiaUnited Kingdom
-
Professor Michael BourkeWithdrawn
-
Medical University of South CarolinaCompletedBarretts Esophagus With DysplasiaUnited States
-
Allegheny Singer Research Institute (also known...Integra LifeSciences CorporationTerminatedBarrett Esophagus | High Grade Dysplasia | EsophagusUnited States
-
Lucid Diagnostics, Inc.RecruitingBarrett Esophagus | Barretts Esophagus With Dysplasia | Esophagus AdenocarcinomaUnited States
Clinical Trials on Diagnostic Test
-
Hospital Clínica KennedyCompletedStroke | Insomnia | Ischemic Heart Disease | Sleep-disordered Breathing | HypersomniaEcuador
-
Hospices Civils de LyonRecruiting
-
Istanbul UniversityRecruitingCleft Lip and Palate | Dental Age EstimationTurkey
-
Hospital St. Joseph, Marseille, FranceRecruiting
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Suleyman Demirel UniversityRecruiting
-
University of ZurichRecruiting
-
Institute of Cardiometabolism and Nutrition, FranceEnrolling by invitationInduced Pluripotent Stem CellsFrance
-
ChroniSense Medical Ltd.Completed
-
Myriad Genetic Laboratories, Inc.Myriad Genetics, Inc.CompletedHereditary CancerUnited States